SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:1010 4283
 

Sökning: L773:1010 4283 > Utility of G protei...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005303naa a2200649 4500
001oai:DiVA.org:umu-190694
003SwePub
008211222s2019 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:3b8afa0a-0f04-49b1-810c-a44ddf0fea40
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1906942 URI
0247 a https://doi.org/10.1177/10104283198588852 DOI
0247 a https://lup.lub.lu.se/record/3b8afa0a-0f04-49b1-810c-a44ddf0fea402 URI
040 a (SwePub)umud (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Ali, Haythamu Umeå University,Umeå universitet,Klinisk immunologi,Onkologi,Department of Pathology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt4 aut0 (Swepub:umu)haal0076
2451 0a Utility of G protein-coupled receptor 35 expression for predicting outcome in colon cancer
264 c 2019-06-28
264 1b Sage Publications,c 2019
338 a electronic2 rdacarrier
520 a The utility of mRNA and protein determinations of G protein-coupled receptor 35, that is, GPR35a (GPR35 V1) and GPR35b (GPR35 V2/3), as indicators of outcome for colon cancer patients after curative surgery was investigated. Expression levels of V1 and V2/3 GPR35, carcinoembryonic antigen and CXCL17 mRNAs were assessed in primary tumours and regional lymph nodes of 121 colon cancer patients (stage I–IV), colon cancer cell lines and control colon epithelial cells using real-time quantitative reverse transcriptase-polymerase chain reaction. Expression of G protein-coupled receptor 35 was investigated by two-colour immunohistochemistry and immunomorphometry. GPR35 V2/3 mRNA, but not V1 mRNA, was expressed in colon cancer cell lines, primary colon tumours and control colon epithelial cells. Haematoxylin and eosin positive (H&E(+)), but not H&E(–), lymph nodes expressed high levels of GPR35 V2/3 mRNA (P<0.0001). GPR35b and carcinoembryonic antigen proteins were simultaneously expressed in many colon cancer tumour cells. Kaplan–Meier and hazard ratio analysis revealed that patients with lymph nodes expressing high levels of GPR35 V2/3 mRNA and, in particular, in the group of patients with lymph nodes also expressing carcinoembryonic antigen mRNA, had a short disease-free survival time, 67 months versus 122 months at 12-year follow-up (difference: 55 months, P = 0.001; hazard ratio: 3.6, P = 0.002). In conclusion, high level expression of G protein-coupled receptor 35 V2/3 mRNA in regional lymph nodes of colon cancer patients is a sign of poor prognosis.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a GPR35b
653 a GPR35 V1 mRNA
653 a GPR35 V2/3 mRNA
653 a CXCL17 mRNA
653 a CEA
653 a colon cancer
653 a qRT-PCR
653 a immunohistochemistry
653 a CEA
653 a colon cancer
653 a CXCL17 mRNA
653 a GPR35 V1 mRNA
653 a GPR35 V2/3 mRNA
653 a GPR35b
653 a immunohistochemistry
653 a qRT-PCR
7001 a AbdelMageed, Manaru Umeå University,Umeå universitet,Klinisk immunologi,Onkologi,Department of Pathology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt4 aut0 (Swepub:umu)maab0124
7001 a Olsson, Linau Umeå University,Umeå universitet,Immunologi/immunkemi4 aut0 (Swepub:lu)li7888ol
7001 a Israelsson, Anneu Umeå University,Umeå universitet,Immunologi/immunkemi4 aut0 (Swepub:umu)aneisn00
7001 a Lindmark, Gudrunu Lund University,Lunds universitet,Kliniska Vetenskaper, Helsingborg,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUBIN Lab- Lunds laboratorium för neurokirurgisk hjärnskadeforskning,Forskargrupper vid Lunds universitet,Clinical Sciences, Helsingborg,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,LUBIN Lab- Lund Brain Injury laboratory for Neurosurgical research,Lund University Research Groups4 aut0 (Swepub:lu)med-gli
7001 a Hammarström, Marie-Louiseu Umeå University,Umeå universitet,Immunologi/immunkemi4 aut0 (Swepub:umu)maha0008
7001 a Hammarström, Stenu Umeå University,Umeå universitet,Immunologi/immunkemi4 aut0 (Swepub:umu)stha0002
7001 a Sitohy, Baselu Umeå University,Umeå universitet,Onkologi4 aut0 (Swepub:umu)balsiy01
7102 a Umeå universitetb Klinisk immunologi4 org
7730 t Tumor Biologyd : Sage Publicationsg 41:6q 41:6x 1010-4283x 1423-0380
8564 u https://doi.org/10.1177/1010428319858885y Fulltext
8564 u https://umu.diva-portal.org/smash/get/diva2:1622367/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://journals.sagepub.com/doi/pdf/10.1177/1010428319858885
8564 u http://dx.doi.org/10.1177/1010428319858885x freey FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-190694
8564 8u https://doi.org/10.1177/1010428319858885
8564 8u https://lup.lub.lu.se/record/3b8afa0a-0f04-49b1-810c-a44ddf0fea40

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy